About Nemysis
Nemysis’ Team has an enviable track record of delivering projects together
Nemysis Management Team and Board of Directors is made up of highly experienced and successful pharmaceutical executives and entrepreneurs, who have an enviable track record of delivering projects together in previous ventures.
Formed in 2017, Nemysis Ltd is an Irish company which has virtual operations and staff geographically distributed worldwide. We focus on functional substances, where our innovative solutions and expertise can successfully target large markets with unmet patient needs.
Nemysis’ therapeutic focus is on gut-mediated disorders, with particular attention to minimise gastrointestinal and other side effects, commonly associated with all other available products.
A diversified, independent platform with multi-product capabilities
We developed IHAT, an iron-based nano-particulate compound to address the effects caused by iron deficiency as well as the adverse side effects common to all currently available therapeutic solutions.
E40 is a new Glutenase, developed to specifically address symptomatic gluten exposure in Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS), two distinct conditions whereby the ingestion of gluten and other components of wheat leads to a series of serious gastrointestinal and other severe reactions.
We operate a diversified, independent platform with multi-product capabilities. In the short term we take products through the Novel Food supplement or Medical Device route, reducing time and cost to market whilst increasing access. Longer term, we continue the development to take these compounds to drug status where required by relevant regulation and based on an out-license co-development approach for drug development for the prescriptions market.
Regardless of the route, all our pre-clinical, clinical and manufacturing development activities are carried out, at every development stage, at GLP and GMP standard.
IHAT – Nano Fe(III)
Harnesses nano technology to mimic normal delivery and absorption of iron to and through the gut for patients with Iron Deficiency, with or without Anaemia.
E40
Breaks down the immunogenic fragments that occur when gluten has been inadvertently ingested.
Matrix Delivery System
Gastro-protection of enzymes and other compounds from harsh gastric environment and safe delivery to the intended site of absorption / action.
Working with key scientific advisors we quickly identify and develop opportunities
Through our rich and varied scientific and clinical network, we identify highly prevalent unmet patient needs and innovative technologies in our chosen field of gut-mediated disorders.
In collaboration with our network within academia and clinicians, and supported by healthcare statistics, and market analysis, we understand, distil and collate opportunities on many different levels.
Our strategy and approach allows us to feed, grow and test ideas rapidly, to quickly assess the feasibility of and then develop any potential project with our scientific and clinical network, from inception to market.
Through our Italian subsidiary, Enteralia Bioscience S.r.l., we demonstrate our belief in our products by marketing them directly within the Italian market, one of the largest for our product types in Europe. This not only demonstrates our confidence in our proprietary products but provides us invaluable insights and experience to optimise routes to market, experience we share with our distribution parters in Italy and internationally.